Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
Nanoscale. 2019 Jan 17;11(3):1177-1194. doi: 10.1039/c8nr08781d.
An intravenously administered drug delivery system should undergo a five-step 'CAPIR' cascade (circulation, accumulation, penetration, internalization and release), and the maximal efficiency of each step is of great importance to obtain the improved final therapeutic benefits and overall survival rate. Here, a pH/matrix metalloproteinase-9 (MMP9) sequentially responsive and continuously structure-transformable nanoparticle assembled from a doxorubicin (DOX)-conjugated peptide was exploited for comprehensively improving the 'CAPIR cascade' and eventually enhancing the therapeutic efficacy. The chimeric peptide can self-assemble into spherical nanoparticles (RGD-sNPs) at pH 7.4 with a particle size of 45.7 ± 5.4 nm. By a combination of passive and active targeting mechanisms, RGD-sNPs achieved efficient accumulation at the tumor site (∼15.1% ID g-1 within 24 h). Both in vitro and in vivo experiments revealed that RGD-sNPs can be transformed into rod-like nanoparticles (S-NFs) triggered by MMP9 that overexpressed in the tumor microenvironment, demonstrating remarkable advantages of deep tumor penetration, prolonged drug retention with ∼3.7% ID g-1 at 96 h, and 2-fold enhanced internalization. Subsequently, S-NFs would respond to the intracellular weakly acidic stimuli to rapidly release DOX for induction of cytotoxicity and apoptosis. Meanwhile, the remaining peptide was further converted into long fibers (length >5 μm) with significant cytotoxicity, thereby exerting a synergistic antitumor effect. Thus RGD-sNPs displayed superior antitumor efficacy and extended the median survival period to 55 days. This provides a new horizon for the exploration of high-performance antitumor nanomedicines.
静脉给药系统应经历一个五步“CAPIR”级联(循环、积累、渗透、内化和释放),每个步骤的最大效率对于获得改进的最终治疗效果和总体存活率非常重要。在这里,开发了一种由阿霉素(DOX)缀合肽自组装而成的 pH/基质金属蛋白酶-9(MMP9)顺序响应和连续结构可变形纳米粒子,用于全面改善“CAPIR 级联”,最终增强治疗效果。该嵌合肽在 pH 7.4 下可自组装成具有 45.7 ± 5.4nm 粒径的球形纳米粒子(RGD-sNPs)。通过被动和主动靶向机制的结合,RGD-sNPs 能够在肿瘤部位实现高效积累(24 小时内约 15.1%ID g-1)。体外和体内实验均表明,RGD-sNPs 可在肿瘤微环境中过度表达的 MMP9 的触发下转化为棒状纳米粒子(S-NFs),表现出显著的深肿瘤渗透优势,延长药物保留时间,96 小时时约为 3.7%ID g-1,内化增强 2 倍。随后,S-NFs 会响应细胞内的弱酸性刺激,迅速释放 DOX 以诱导细胞毒性和细胞凋亡。同时,剩余的肽进一步转化为具有显著细胞毒性的长纤维(长度>5μm),从而发挥协同抗肿瘤作用。因此,RGD-sNPs 表现出优异的抗肿瘤功效,并将中位生存时间延长至 55 天。这为探索高性能抗肿瘤纳米药物提供了新的视野。